TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02947737

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Amniotic membrane dressing
Description: We will place an amniotic membrane dressing on the donor site

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gentamicin and xeroform dressing
Description: We will place xeroform, gentamicin and telfa on the donor site
Study: NCT04168671

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Continuous laryngoscopy during exercise test
Description: Continuous laryngoscopy during exercise test

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Continuous laryngoscopy during exercise test
Description: Continuous laryngoscopy during exercise test
Study: NCT04974775

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood collection
Description: Sampling on admission to ICU (all patients)

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood collection
Description: Sampling on admission to ICU (all patients)

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood collection
Description: Sampling on admission to ICU (all patients)

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood collection
Description: Sampling on admission to ICU (all patients)

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood collection
Description: Sampling on admission to ICU (all patients)

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood collection, serial sampling
Description: Additional sampling to admission samples in~1. the Cardiac Arrest group after 12 and 48 hours~2. the Covid-19 group on day 2 and 7 while in the ICU~3. the Covid-19 group after 3 and 12 months.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood collection, serial sampling
Description: Additional sampling to admission samples in~1. the Cardiac Arrest group after 12 and 48 hours~2. the Covid-19 group on day 2 and 7 while in the ICU~3. the Covid-19 group after 3 and 12 months.
Study: NCT02821962

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sedentary prompts from a VTAP device
Study: NCT01344447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadobutrol (Gadovist, BAY86-4875)
Description: A single bolus injection of approx. 0.1mmol/kg
Study: NCT03219060

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interviewing for smoking cessation in nurses
Description: Intervention, four one-to-one sessions on an approximately weekly basis, with 3 components: MI context, toolkit, and relapse prevention. The sessions were embedded in a MI context and followed two phases: exploratory and resolutive. The former explored the potential ambivalence that nurses experienced and constructed motivation for change; the latter reinforced the decision to quit and developed a change plan. Participants could choose over a range of tools: some more helpful in the exploratory phase (i.e. decisional balance sheet) and others in the resolutive phase (i.e. problem solving skills). The third component was directed at maintenance strategies. The therapy stayed with the nurses in terms of where they were in relation to they readiness for change.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief advice
Description: Brief advice based on 5As
Study: NCT03483493

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure Response Prevention for tics
Description: The intervention consists of evidence-based interventions adapted from previously published treatment manuals on Exposure and Response Prevention (ERP) and established behavioural intervention for tics protocols. Each of the 10 modules includes age-appropriate texts, animations and exercises. Prticipants are instructed to practice suppressing their tics, this is known as 'response prevention'. Then, with the help of their parent/carer, the participant is instructed to provoke premonitory urges (the urge to tic often felt before the tic is expressed) and try to supress the need to express/demonstrate the tic, this known as 'exposure'.
Study: NCT01556672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Adalimumab will be administered sub-cutaneously to all patients entering the study with a loading dose of 80 mg followed by 40 mg at week 1 and 40 mg every other week. Patients who did not have small bowel lesions detected will be in the study and receive adalimumab until week 12. Patients who had small bowel lesions detected will be in the study and receive adalimumab until week 24.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Capsule endoscopy
Description: All patients will undergo capsule endoscopy (EndoCapsule EC type 1; Olympus) to treatment initiation (adalimumab) in order to detect the presence of small bowel lesions suggestive of Crohn's disease. Twenty-four (24) weeks after treatment with adalimumab was initiated, patients for whom small bowel lesions were detected will undergo a second capsule endoscopy to evaluate changes in bowel inflammation.
Study: NCT01459172

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: limonene containing massage oil
Description: daily massage application to the breast for 4 weeks
Study: NCT01569529

Intervention type: BEHAVIORAL
Intervention: Online advertisement
Description: Internet advertisement with messages tailored for young adult smoker's motivated to quit
Study: NCT03865329

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention- Home-based Pulmonary Rehabilitation
Description: Home-based Pulmonary Rehabilitation (PR) with health coaching using a remote system that will allow patients to complete PR at home. The program involves upper and lower extremity exercises, self-report of symptoms (fatigue, breathlessness, physical activity and overall well-being).
Study: NCT04248569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNAJB1-PRKACA peptide vaccine
Description: 1. DNAJB1-PRKACA peptide vaccine: Day 1, 8, 15 of cycle 1 and Day 1 of cycle 2, 3, 4 and 5 (priming phase). Boost vaccinations: every 3 cycles beginning C6D1. For Cohort A-(Initial) only: Patients with FLC cancer with no prior checkpoint inhibitor therapy treatment.~2. DNAJB1-PRKACA peptide vaccine: Day 1, 8, 15 of cycle 1 and on Day 1 of cycle 2, 3 and 4 (priming phase). Boost vaccinations: every 3 cycles beginning C5D1.~   * Cohort A-(Expansion): Patients with FLC cancer with no prior checkpoint inhibitor treatment.~  * Cohort B: Patients with FLC cancer with prior checkpoint inhibitor treatment.~  * Cohort C: Patients with non-FLC cancer (solid tumors) with prior checkpoint inhibitor treatment eligible.~3. Drug: 0.3 mg DNAJB1-PRKACA peptide vaccine + 0.5mg Poly-ICLC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 1. Cohort A (Initial): Nivolumab 3mg/kg will be administered as a 30 minute IV infusion (-10/+15min) on Day 1 of Cycle 2-5 during the priming phase. Boost/maintenance vaccinations will be administered as a flat dose of 480mg every 4 weeks starting on Day 1 of Cycle 6.~2. Cohort A (Expansion), B and C: Nivolumab 3mg/kg will be administered as a 30 minute IV infusion (-10/+15min) on Day 1 of Cycle 1-4 during the priming phase. Boost/maintenance vaccinations will be administered as a flat dose of 480mg every 4 weeks starting on Day 1 of Cycle 5.~3. Drug: 3mg/kg and 480mg IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: 1. Cohort A (Initial): Ipilimumab (1 mg/kg) will be administered as a 30 minute IV infusion (-10/+15min) on Day 1 of Cycles 2, 3, 4 and 5 of the study, every 3 weeks of the priming phase.~2. Cohort A (Expansion), B and C: Ipilimumab (1 mg/kg) will be administered as a 30 minute IV infusion (-10/+15min) on Day 1 of Cycles 1, 2, 3 and 4 of the study, every 3 weeks of the priming phase.~3. Drug: 1mg/kg IV
Study: NCT04966338

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ocrelizumab (CinnaGen, Iran)
Description: Ocrelizumab (CinnaGen, Iran) will be administered via intravenous (IV) infusion.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ocrelizumab (Roche, Switzerland)
Description: Ocrelizumab (Roche, Switzerland) will be administered via intravenous (IV) infusion.
Study: NCT04355962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Sedation with sevoflurane (etSevo 0.5-1.5 Vol %) for 48 hours in patients with COVID-19 ARDS

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous drug
Description: Intravenous sedation in control group will be continued as initiated at the ICU e.g. propofol, fentanyl, midazolam, dexmedetomidine
Study: NCT00003491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antineoplaston therapy (Atengenal + Astugenal)
Description: Patients with Stage IV Lung Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Study: NCT02135224

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Study: NCT00749775

Intervention type: DRUG
Intervention: Selara
Description: Treatment should be initiated at 25 mg once daily and titrated to the recommended dose of 50 mg once daily, preferably within 4 weeks as tolerated by the patient. Selara may be administered with or without food.
Study: NCT03108846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: 5-15 mg/day (target: 15mg/day if tolerated)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Masked placebo
Study: NCT02096458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole
Description: Dexlansoprazole delayed-release orally disintegrating tablets
Study: NCT02619409

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine Only
Description: The bupivacaine only group will receive bupivacaine 0.5% 3cc plus sterile saline 0.1cc.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EPI25
Description: The EPI25 group will receive bupivacaine 0.5% 3cc, epinephrine 1:1000 0.025cc, and sterile saline 0.075cc.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EPI50 group
Description: The EPI50 group will receive bupivacaine 0.5% 3cc, epinephrine 1:1000 0.05cc, and sterile saline 0.05cc

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EPI75 group
Description: The EPI75 group will receive bupivacaine 0.5% 3cc, epinephrine 1:1000 0.075cc, and sterile saline 0.025%.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EPI100 group
Description: The EPI100 group will receive bupivacaine 0.5% 3cc, and epinephrine 1:1000 0.1cc.
Study: NCT03123159

Intervention type: DIAGNOSTIC_TEST
Intervention: DxN HBV Assay
Description: Molecular diagnostic test to detect Hepatitis B
Study: NCT03712475

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: pharmacokinetic study under fasting conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: pharmacokinetic study under fasting conditions
Study: NCT02487394

Intervention type: PROCEDURE
Intervention: Exhaled Breath Condensate (EBC)
Description: Collection of EBC condensate

Intervention type: PROCEDURE
Intervention: Exhaled Breath Condensate (EBC)
Description: Collection of EBC condensate
Study: NCT00953329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alefacept
Description: Alefacept 15 mg IM once a week were to be administered for 12 weeks, which is the FDA approved dosage, duration, and frequency. This study allowed an additional 8 doses if subject did not achieve a 'clear' response with the original 12 weeks of treatment. Each enrolled subject must have failed a response to anti-TNF therapy prior to entering this study.
Study: NCT03722329

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eculizumab
Description: Eculizumab Injection. 300 mg, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eculizumab
Description: Eculizumab Injection. 300 mg, single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eculizumab
Description: Eculizumab Injection. 300 mg, single dose
Study: NCT00628290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Capsules, 3 times daily, 200 mg, 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amisulpride
Description: Capsules, 3 times daily, 200 mg, 4 weeks
Study: NCT04700748

Intervention type: RADIATION
Group type: OTHER
Intervention: Brain metastases radiation
Description: Brain metastases radiation according to clinical practice.
Study: NCT01437553

Intervention type: DEVICE
Group type: OTHER
Intervention: iMAP
Description: IVUS and iMAP analysis for acute coronary syndromes
Study: NCT02146482

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sit-stand computer workstation
Description: A sit-stand computer workstation allows one to sit or stand throughout the day while maintaining continued use of one's computer.
Study: NCT01515683

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Only support from an anaesthetic nurse on the surgery ward
Description: Additional staff are only present if required by law.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Support: a theatre nurse + an anaesthetic nurse
Description: Theatre nurse stay with the patient, follow her to the operating table and stays with her until she is anaesthetized

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Support: a nurse from the ward + an anaesthetic nurse
Description: A nurse from the ward follows the patient to the operating table and stays with her until she is anaesthetized.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Optional relative supports
Description: Optional relative follows the patient to the operating table and stays with her until she is anaesthetized
Study: NCT03100708

Intervention type: PROCEDURE
Intervention: PIPAC
Description: * Cisplatin 7.5 mg/m2 body surface in 150 ml NaCl 0,9% + Doxorubicin 1.5 mg/m2 body surface in 50 ml NaCl 0,9% in patients with ovarian, gastric, pancreatic cancer and in primary peritoneal tumors.~* Oxaliplatin 92 mg/m2 body surface in 150 ml dextrose solution in patients with colorectal cancer.~The chemotherapeutics will be admitted to the abdomen by a nebulizer at a pressure of 200 psi and 12 mmHG with 0.5 mL/sec. Afterwards the chemotherapeutics can react for 30min before the abdominal gas will be drained to the clinics filtering system.
Study: NCT04066426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: naproxen sodium+codeine phosphate, naproxen sodium+dexamethasone, naproxen sodium, paracetamol
Description: NSAID, steroid, opioid, paracetamol and combinations of this drugs can be used in temporomandibular disorders.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: naproxen sodium+codeine phosphate, naproxen sodium+dexamethasone, naproxen sodium, paracetamol
Description: NSAID, steroid, opioid, paracetamol and combinations of this drugs can be used in temporomandibular disorders.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: naproxen sodium+codeine phosphate, naproxen sodium+dexamethasone, naproxen sodium, paracetamol
Description: NSAID, steroid, opioid, paracetamol and combinations of this drugs can be used in temporomandibular disorders.
Study: NCT00732498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: 250 mg/m2/day IV over 1 hour days 1,2,3,4 every 28 days for 2 cycles. If bone marrow \<25% involved and expected biodistribution after 2 cycles yttrium-90-ibritumomab tiuxetan (Zevalin) to be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 40 mg/day IV over 1 hour days 1,2,3,4 every 28 days for 2 cycles. If bone marrow \<25% involved and expected biodistribution after 2 cycles yttrium-90-ibritumomab tiuxetan (Zevalin) to be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 2000 mg/m2 IV over 2 hours days 4 every 28 days for 2 cycles. If bone marrow \<25% involved and expected biodistribution after 2 cycles yttrium-90-ibritumomab tiuxetan (Zevalin) to be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 25 mg/m2/day IV at 1mg/min days 1,2,3,4 every 28 days for 2 cycles. If bone marrow \<25% involved and expected biodistribution after 2 cycles yttrium-90-ibritumomab tiuxetan (Zevalin) to be administered.
Study: NCT01116167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole -Berberine
Description: Letrozole~2.5 mg letrozole daily from day 5 of the menses for 5 days for month 1 to 3, 5.0 mg letrozole daily from day 5 of the menses for 5 days for month 4 to 6.~Berberine~1.5g daily for 6 month.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Letrozole~2.5 mg letrozole daily from day 5 of the menses for 5 days for month 1 to 3, 5.0 mg letrozole daily from day 5 of the menses for 5 days for month 4 to 6.~Berberine Placebo~5 tablet tds for 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Berberine
Description: Berberine~1.5g daily for 6 month.~Letrozole placebo~1 tablet daily from day 5 of the menses for 5 days for month 1 to 3, 2 tablets daily from day 5 of the menses for 5 days for month 4 to 6.
Study: NCT05217576

Intervention type: DEVICE
Group type: OTHER
Intervention: NBM-200
Description: Finger Prick and Venipuncture

Intervention type: DEVICE
Group type: OTHER
Intervention: NBM-200
Description: Finger Prick and Venipuncture
Study: NCT00955617

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced MRA - Imaging examination
Description: Administration of 0.1 mmol/kg of contrast product (Dotarem and Gadovist)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced MRA - Imaging examination
Description: Administration of 0.1 mmol/kg of contrast product (Dotarem and Gadovist)
Study: NCT01313065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX15/2503
Description: Dose escalation will begin at low doses and will gradually increase in each future cohort. The current trial design provides for 7 study cohorts with a 20 mg/kg expansion phase.
Study: NCT00732498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 250 mg/m2 slow IV over days 1, then 7,8 or 9 prior to In Zevalin. Rituximab + Zevalin regimen is given 4-6 weeks after completion of 2 cycles of ESHAP. Treatment can be completed within 7-9 days in an outpatient setting.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: In-Zevalin
Description: 5 mCi slow IV push over 10 minutes days 1. Given within 4 hours after Rituximab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Y-Zevalin
Description: Platelet counts from 100,000/mm3 to 149,000/mm3 will receive 0.3 mCi/kg. Platelet counts from \>/= 150,000/mm3 will receive 0.4 mCi/kg, not to exceed 32 mCi Y Zevalin. Slow IV push over 10 minutes, days 7,8 or 9 given within 4 hours after Rituximab.
Study: NCT03733665

Intervention type: OTHER
Intervention: Patients admitted to hospital
Description: Data is captured in HES for all patient interactions with the NHS (each episode) in England. All patients admitted for heart failure have data captured in the National Heart Failure Audit.
Study: NCT03483493

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation for tics
Description: The comparator intervention reviews the definition of tics, natural history, common presentations, prevalence, aetiology, risks and protective factors and strategies for describing tics to other people etc. Problem-solving and development of expertise in tic disorders is emphasised. The intervention includes strategies for promoting positive behaviours which will be rewarded by a parent as a parallel element to the tic control practice in the behavioural therapy arm. There is no information on tic control within the management package.
Study: NCT02154841

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaire, taste test, visual food test
Study: NCT02240511

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: RE and BCAA Supplementation
Description: RE: Resistance Exercise BCAA: Branched Chain Aminoacids
Study: NCT04489862

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: αPD1-MSLN-CAR T cells
Description: Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of αPD1-MSLN-CAR T cells. During αPD1-MSLN-CAR T cells production, subjects will receive cyclophosphamide for the purpose of lymphocytes depletion，Cyclophosphamide 300 mg/m2/day IV infusion on days -5, -4 and -3. After lymphodepletion, subjects will receive one dose treatment with αPD1-MSLN-CAR T cells by intravenous (IV) injection. The initial dose of 1×10\^5 CAR+ T cells/kg will be infused on day 0.
Study: NCT03312504

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular training program
Description: This is a 15-minute warm-up program designed to be implemented at the beginning of junior high school physical education classes. This warm-up is comprised of 15 components; nine of which are aerobic exercises (forward running, forward run with skipping, forward run with knee lifts, forward run with heel kicks, sideways shuffles, zigzag running, forward running with intermittent stops, speed runs, and squat/skate jumps), and six of which are balance/strengthening exercises (front plank, side plank, nordic hamstring exercise, lunges, balancing on the wobble board, and balancing on foam balance pads).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard-of-practice Warm-up (Control)
Description: This is a 15-minute warm-up program designed to be implemented at the beginning of junior high school physical education classes. This warm-up is comprised of 16 components; seven of which are aerobic exercises (forward running, forward running with arm swings, side shuffling, lunging, skipping, arm running with arm swings, and cool-down running), and nine of which are static stretching exercises (standing quadriceps, standing hamstrings, standing calf, standing groin, rotating ankle, lunges, standing shoulder, standing triceps, standing neck).
Study: NCT00538434

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Reslizumab
Study: NCT02240511

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistance Exercise
Study: NCT02919072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroprocaine
Description: The 20 mL epidural anaesthetic solution will be administered as follows: 5 mL of the study anaesthetic solution will be given epidurally and the block will be assessed after 2 minutes from the first injection using cold, pinprick and touch. Then intrathecal placement will be excluded and a further 15 mL of the study anaesthetic solution will be administered epidurally. Two minutes after the start of the second injection, the sensory block will be re-assessed using cold, pinprick and touch. In case of pain or discomfort a 6 mL epidural top-up of the same anaesthetic will be administered.
Study: NCT00538434

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Reslizumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Reslizumab